Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
You may also be interested in...
Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.
At House hearing, PhRMA representative cites introduction of innovative delivery systems while GPhA exec points to manufacturing costs; state attorneys general file Suboxone 'product hopping' suit.
The company will move forward with 70 pipeline candidates following the closing of the Allergan merger, Senior VP-Brand R&D David Nicholson said during the company’s first quarter earnings call.